We assessed the prognostic performance using PFS as the endpoint, in breast cancer patients from two different hospitals, for all patients as well as for the clinically relevant ER+/HER2- subgroup and the intermediate-risk subgroup. This evidence concerns the gene ERBB2 and breast cancer.